About Osteoarthritis PowerPoint Presentation

Slide 1 -

Osteoarthritis Uyenvy Pham, M.D. Swedish Geriatric Fellow March 22, 2011

Slide 2 -

Overview Definition and Risk Factors Idiopathic vs. Secondary OA Clinical Features Diagnosis Radiologic Features ACR OA dx for knees, hands, hips Goals of Treatment Non-pharmacologic treatment Pharmacologic treatment Surgical Considerations

Slide 3 -

Osteoarthritis Articular cartilage failure induced by a complex interplay of genetic, metabolic, biochemical, and biomechanical factors With secondary components of inflammation Initiating mechanism is damage to normal articular cartilage by physical forces (macrotrauma or repeated microtrauma) Not necessarily normal consequence of aging

Slide 4 -

Risk Factors Age Female versus male sex Obesity Lack of osteoporosis Occupation Sports activities Previous injury Muscle weakness Proprioceptive deficits Genetic elements Acromegaly Calcium crystal deposition disease

Slide 5 -

Idiopathic Osteoarthritis Localized or generalized forms Localized OA most commonly affects the hands, feet, knee, hip, and spine Other joints less commonly involved shoulder, temporomandibular, sacroiliac, ankle, and wrist joints Generalized OA three or more joint sites

Slide 6 -

Patterns of Presentation Monoarticular in young adult Pauciarticular, large-joint in middle age Polyarticular generalized Rapidly progressive Secondary to trauma, congenital abnormality, or systemic disease

Slide 7 -

Secondary Osteoarthritis Trauma Congenital or developmental disorders Calcium pyrophosphate dihydrate deposition disease (CPPD) Other bone and joint disorder osteonecrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, and Paget disease of bone Other diseases diabetes mellitus, acromegaly, hypothyroidism, neuropathic (Charcot) arthropathy, and frostbite

Slide 8 -

Clinical Features Age of Onset > 40 years Commonly Affected Joints Cervical and lumbar spine First carpometacarpal joint Proximal interphalangeal joint Distal interphalangeal joint Hip Knee Subtalar joint First metarsophalangeal joint

Slide 9 -

Uncommonly Affected Joints Shoulder Wrist Elbow Metacarpophalangeal joint TMJ SI Ankle

Slide 10 -

Clinical Diagnosis Symptoms Pain Stiffness Gelling Physical examination Crepitus Bony enlargement Decreased range of motion Malalignment Tenderness to palpation The more features, the more likely the diagnosis

Slide 11 -

Differential Diagnosis Rheumatoid Arthritis Gout CPPD (Calcium pyrophosphate crystal deposition disease) Septic Joint Polymyalgia Rheumatica

Slide 12 -

Synovial fluid analysis Severe, acute joint pain is an uncommon manifestation of OA Clear fluidWBC <2000/mm3 Normal viscosity

Slide 13 -

Radiographic Features Joint space narrowing Subchondral sclerosis Marginal osteophytes Subchondral cyst

Slide 14 -

Joint Space Narrowing OA typically asymmetrical Paget’s disease

Slide 15 -

Subchondral Sclerosis Increased bone density or thickening in the subchondral layer

Slide 16 -

Osteophytes Bone spurs

Slide 17 -

Subchondral Cysts Fluid-filled sacs in subchondral bone

Slide 18 -

OA of the Knee: Classic Criteria 1. Greater than 50 years of age 2. Morning stiffness for less than 30 minutes 3. Crepitus on active motion of the knee 4. Bony tenderness 5. Bony enlargement 6. No palpable warmth 3 of 6 criteria give sensitivity of 95% and specificity of 69%

Slide 19 -

OA of the Knee: Addition of X-rays ACR Criteria of: 1. knee pain 2. radiographic evidence of osteophytes 3. one of three additional findings: age greater than 50 years of age morning stiffness of less than 30 minutes crepitus Sensitivity and specificity for OA of 91 and 86%

Slide 20 -

Hand Osteoarthritis Diagnosis by hand pain Plus at least three of the following four features: 1. Hard tissue enlargement of 2 or more of 10 selected joints. The 10 selected joints are the second and third distal interphalangeal (DIP) joints, the second and third proximal interphalangeal (PIP) joints, and the first carpometacarpal (CMC) of both hands 2. Hard enlargement of two or more DIP joints 3. Fewer than three swollen metacarpophalangeal (MCP) joints 4. Deformity of at least 1 of the 10 selected joints Sensitivity and Specificity for hand OA of 94 and 87%

Slide 21 -

Hip Osteoarthritis Diagnosis Use history, physical, laboratory, and radiographic features (ACR) Hip Pain, plus at least two of the following three features: 1. ESR of less than 20 mm/h 2. Radiographic osteophytes 3. Joint space narrowing on radiography Sensitivity of 89 percent and a specificity of 91 percent

Slide 22 -

ppt slide no 22 content not found

Slide 23 -

Typical OA work-up History PE Consider following (especially if OA of knees or hips) Erythrocyte sedimentation rate (ESR) Rheumatoid factor titers Evaluation of synovial fluid Radiographic study of affected joints

Slide 24 -

Overview Definition and Risk Factors Idiopathic vs. Secondary OA Clinical Features Diagnosis Radiologic Features ACR OA dx for knees, hands, hips Goals of Treatment Non-pharmacologic treatment Pharmacologic treatment Surgical Considerations

Slide 25 -

Goals of Treatment Control pain and swelling Minimize disability Improve the quality of life Prevent progression Education Chronic Condition and Management

Slide 26 -

Non-pharmacologic Treatment Weight Loss Ten-pound weight loss over 10 years decreased the odds for developing knee OA by 50% Even a modest amount of weight loss may be beneficial Rest Short period of time, typically 12-24 hours Prolonged rest can lead to muscle atrophy and decreased joint mobility

Slide 27 -

Non-pharmacological Treatment Physical Therapy “Manual therapy" may be more beneficial than exercise programs that focus on muscle strengthening, endurance training, and improved coordination May be more beneficial in those with mild OA Ultrasound therapy may have some benefit based on 2009 Cochrane Review

Slide 28 -

Tens SOR B Safety/Tolerability: High Efficacy: Medium 20 points more effective on scale of 100 compared to placebo Few long term studies Price: Low to medium

Slide 29 -

Non-pharmacologic Treatment Knee Braces/Shoe Inserts - SOR C Cochrane reports a “sliver of benefit” 73% taping for 3 weeks reported improvement (elastic knee sleeve) Price: Low $30 Acupuncture Cochrane January 2010 Very small improvements in pain and physical function after 8 weeks and 26 weeks A lot seems to be placebo effect due to incomplete blinding Price: Medium to high, 1000$ over 3-4 months Reasonable to offer if patient resistant to conventional treatment and wants to try alternative therapies

Slide 30 -

Non-pharmacological Treatment Exercise – focus on low load exercise Tai Chi Yoga Swimming Biking Walking Most important aspect to counsel patients for prevention and treatment Cochrane Review 2009 compares efficacy to NSAIDs in short-term benefits Heat and Cold Lack of convincing data despite being commonly used

Slide 31 -

Acetaminophen Cochrane 2009 Review NSAIDs are superior to acetaminophen for improving knee and hip pain in people with OA Treatment effect was modest Median trial duration was only six weeks In OA subjects with moderate-to-severe levels of pain NSAIDs > Acetaminophen > Placebo NNT for Acetaminophen 4 to 16 1000mg three to four times daily

Slide 32 -

NSAIDs Tend to avoid for long-term use Rash and hypersensitivity reactions Abdominal pain and gastrointestinal bleeding Impairment of renal, hepatic, and bone marrow function, and platelet aggregation Central nervous system dysfunction in the elderly Low dose ibuprofen (less than 1600 mg/day) may have less serious GI toxicity Nonacetylated salicylates (salsalate, choline magnesium trisalicylate), sulindac, and nabumetone appear to have less renal toxicity Indomethacin should be avoided for long-term use in patients with hip OA associated with accelerated joint destruction

Slide 33 -

Topical NSAIDs A 2004 meta-analysis included 13 trials involving almost 2000 patients Randomly assigned to topical NSAID, oral NSAID, or placebo Significant short term (one to two weeks) efficacy for pain relief and functional improvement when topical NSAIDs were compared to placebo Effect was not apparent at three to four weeks Topical NSAIDs were generally inferior to oral NSAIDs However topical route was safer than oral use Topical Diflofenac (1% gel or patch)

Slide 34 -

COX-2 Inhibitors COX-2 inhibitors appear to be as effective NSAIDs Associated with less GI toxicity However increased risk of CV events Use of low dose ASA may negate the GI sparing effects of COX-2 inhibitors Those who are receiving low dose aspirin and a COX-2 selective agent may benefit from antiulcer prophylaxis

Slide 35 -

Capsaicin Capsaicin Ointment 0.025% (qid) & 0.075% (bid) Principle ingredient of chili peppers (substance P) Love It! Tolerability: Medium 50% experience burning which wanes 50% decrease in pain, 25% with placebo Price: 15$ per month Apply 2-4 times per day

Slide 36 -

Glucosamine Glucosamine Sulfate 1500mg po daily Supplement, typically not covered Cochrane 2009 Rotta preparation glucosamine was superior to placebo in the treatment of pain and functional impairment Non-Rotta preparation failed to show benefit Majority of trials that have evaluated the effectiveness of glucosamine sulfate demonstrated significant clinical benefits Glucosamine hydrochloride trials are scarce and much less convincing Bottom-Line, most likely beneficial if Rotta brand and Sulfate formulation, not HCL

Slide 37 -

Injections Corticosteroid Safety: High for short-term use, data on frequency and degree of use is limited. Study of pt’s receiving 8 injections over 2 year period showed no ill effects in comparison with pt’s receiving placebo. Tolerability: Medium to high Efficacy: Low to medium. Modest benefit. 16 point reduction in pain on 100-point scale for one month. Price: Low, 100$-200$ SOR A

Slide 38 -

Hyaluronic Injections of Knees Safety: High Tolerability: Medium. Small number pts get flare up of symptoms. Efficacy: Low. Recent Meta-analyses and reviews small clinical effect. 75% were satisfied with treatment. Lasts 3-4 months. Price: High. 3 injections costs $700 to $1000 per injection. Claims of substantial savings d/t delayed joint replacement. SOR A

Slide 39 -

Narcotics for Refractory Pain Vicodin/Oxycodone Safety: Medium Tolerability: Medium Constipation, somnolence, mental status changes Price: Low,<$20 per month with vicodin Use of opiates indicated in those who are not candidates for surgery and who continue to have moderate to severe pain despite being on NSAIDs or selective cyclooxygenase (COX)-2 inhibitors

Slide 40 -

Arthroscopic Interventions Controversial Arthroscopic debridement with lavage Sham-surgery versus arthroscopic lavage/debridement study Remove loose pieces of bone and cartilage Resurface (smooth out) bones

Slide 41 -

Prosthetic Joints Commonly of the hip or knee or shoulder Several types: metal, plastic, ceramic Last 10-15 years or more About 10% need to be redone Usually a treatment of “last resort”

Slide 42 -

Joint Replacement Surgical candidate? Often greater improvement in pain rather than function Recovery can be strenuous and lengthy Infection rate 1% Low mortality 0.6% to 0.7% Complications include thrombo-embolic events 5%

Slide 43 -

Education and Self-Help Understand the disease Reduce pain but remain active Clear Functional goals Cope physically, emotionally, and mentally Have greater control over the disease Build confidence

Slide 44 -

References Osteoarthritis-How to best avoid surgery. Journal of Family Practice. July 2009 Osteoarthritis: Diagnosis and Therapeutic Considerations. AAFP. March 1, 2002. FPIN’s Clinical Inquiries. Glucosamine and Chondroitin for Osteoarthritis. April 1, 2006. Cochrane Review. July 2009. Therapeutic ultrasound for osteoarthritis of the knee or hip. Cochrane Review. January 2009. Aquatic exercise for the treatment of knee and hip osteoarthritis. Cochrane Review. July 2009. Exercise for osteoarthritis of the knee. Cochrane Review. January 2009. Acetaminophen for osteoarthritis. Cochrane Review. January 2009. Braces and orthoses for treating osteoarthritis of the knee. Cochrane Review. October 2009. Glucosamine therapy for treating osteoarthritis.

Slide 45 -

Questions?